Triage Survey for Cardiovascular, Obesity, and Related Endocrine Trial Eligibility
NCT06412536 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2024-06-11
Summary
SWIFT-CORE-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, comorbidities, and current symptoms. Site staff may collect vital signs, urine drug screens, blood draws, and urine pregnancy tests. A doctor will review medical history with the participant to determine study suitability via clinical interview. The doctor may reach out to the patient's current treating physicians and pharmacies to determine eligibility for clinical trials.
Conditions
- Cardiovascular Diseases
- Obesity
- PreDiabetes
- Diabetes Type 2
- Metabolic Syndrome
Interventions
- OTHER
-
Blood work
Blood work on some participants to review eligibility for future clinical trials
Sponsors & Collaborators
-
Brooklyn Clinical Research
lead NETWORK
Principal Investigators
-
Ammara Mushtaq, MD · Brooklyn Clinical Research
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-05-30
- Primary Completion
- 2029-04-10
- Completion
- 2029-04-17
Countries
- United States
Study Locations
More Related Trials
-
To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101
NCT01462786 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment
NCT00768209 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
NCT00099450 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function
NCT07076030 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)
NCT05192356 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)
NCT06658626 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
NCT02045966 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants
NCT03210909 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
NCT07104162 ·Status: RECRUITING ·Phase: PHASE1
-
Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers
NCT02393950 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
NCT05707390 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects
NCT07027982 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants
NCT05981963 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
NCT06295796 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
NCT04639115 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole
NCT04139226 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects
NCT02225626 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of TAK-279 in Adults With or Without Liver Damage
NCT05976321 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy Men to Test How BI 1569912 is Processed in the Body
NCT06520553 ·Status: COMPLETED ·Phase: PHASE1
-
Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
NCT02154022 ·Status: ENROLLING_BY_INVITATION
-
Microdialysis and Pharmacokinetic Study of TR-701
NCT00666601 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)
NCT07049939 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants
NCT06640920 ·Status: COMPLETED ·Phase: PHASE1
-
iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
NCT05740280 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers
NCT03500627 ·Status: COMPLETED ·Phase: PHASE1